NanoViricides Inc. (NNVC)

[changes_iv]

Yes, we do have competition. So did Secretariat when it won the first race of the triple crown. Many didn't know Secretariat then, as it is the case today with NanoviriCides, Inc. For many today the bio-nanotechnology employed by NanoViricides, Inc. is new and not well known. Those that are interested in this nano-tech science, like myself, better understand it because of what I read out there in the WWW and what I read/learn from posters in this forum/board.

NanoViricides, Inc. has other well-seasoned companies providing guidance because we want to get it right the first time.

=> The Company engaged the consulting firm Coté Orphan Consulting (COC), headed by Dr. Tim Coté, to assist with our DengueCide orphan drug applications to both the US FDA and the E
DengueCide is a nanoviricide® that has shown very high effectiveness in an animal model of dengue virus infection. These animal studies were conducted in the laboratory of Dr. Eva Harris, Professor of Public Health and Infectious Diseases at the University of California, Berkeley. Professor Harris has developed a mouse model of antibody-dependent-enhancement (ADE) of dengue infection that simulates dengue hemorrhagic fever (DHF/DHSS) using a special laboratory mouse strain called AG129.

In humans DHF/DHSS is associated with a high fatality rate. In this model, infection with a dengue virus, when the mice are left untreated, is 100% fatal. In contrast, in the same study, animals treated with NanoViricides' DengueCide achieved an unprecedented 50% survival rate. <=

more: http://www.marketwatch.com/story/nanoviricides-reports-that-the-denguecidetm-orphan-drug-application-has-been-submitted-and-received-by-the-european-medicines-agency-2013-09-03

We have competition but it won't be long before people discover that we are out in front of the competition and "DengueCide is the only game in town" ~ Dr. Anil Diwan